Efficacy and safety of Telitacicept in IgA nephropathy and its impact on urinary Gd-IgA1: insights from a real-world study.

Front Immunol · 2026 · PMC13022593 · PMID 41909683

Europe PMC DOI

hedged sentence

0.3550

closest p · 7.1× alpha

0.3550

boldest claim

The sentences

did not reach statistical significanceP = 0.355not close (p > 0.1)

Urinary Gd-IgA1 normalized to ACR trended downward after treatment, but this change did not reach statistical significance ( Figure 6C , P = 0.355). 3.5.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.